Back
Article
Canaccord Genuity Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $74
Benzinga Newsdesk  |  Feb 20, 2026 20:51  |  Source: www.benzinga.com
Canaccord Genuity analyst Whitney Ijem initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and announces Price Target of $74.
Comments
  • No comments yet. Be the first to comment!

Login to comment